Interestingly, and distinct from our observations with anti-RPA194 antibodies in SSc, a sufficient number of cancers emerged in anti-CCAR1–positive patients over time to demonstrate that these cancers were diagnosed later after DM presentation and were more localized than those occurring in patients with anti–TIF1-γ antibodies alone. Here, CCAR1 is linked to cancer.